



ABSA INTERNATIONAL

1200 Allanson Road • Mundelein, IL 60060-3808 • 866-425-1385 • Fax: 847-566-4580 • E-mail: info@absa.org • Web Site: www.absa.org

President

Melissa Morland, MS, RBP, CBSP
University of Maryland—Baltimore
714 West Lombard Street
Baltimore, MD 21201
410-706-7845
mmorland@af.umaryland.edu

President-Elect

Maureen O'Leary, PhD, CBSP
Dartmouth College
37 Dewey Field Road, Suite 6216
Hanover, NH 03755
603-646-1762
maureen.o'leary@dartmouth.edu

Secretary Pro Tem

Krista Murray, RBP, CBSP
University of Delaware
222 Chapel Street, 132 GSB
Newark, DE 19716
302-831-1433
klmurray@udel.edu

Treasurer

James Klenner, MSc, MPH, MPA, RBP, CBSP
Indiana University—Purdue University Indianapolis
980 Indiana Avenue, Room 4428
Indianapolis, IN 46202
317-274-2830
jklenner@iupui.edu

Past-President

Marian M. Downing, RBP, CBSP
409 Harborside Way
Kemah, TX 77565-2997
847-209-8201
mmdowning1@gmail.com

Councilors

Julie A. Johnson, PhD, CBSP (16)
Kelly J. Flint, RBP, CBSP, SM(NRCM) (17)
Patrick Condreay, PhD, RBP (18)
Barbara Owen, RBP, CBSP, SM(NRCM) (18)

2016 Biosafety Conference Chairpersons

Exhibitors Advisory Committee
Brandon Rosendahl

Local Arrangements Committee
Patrick Conley, CBSP

Scientific Program Committee
Darlene Ward, RBP

Executive Director

Edward J. Stygar, III, MBA, CAE
ed@absaoffice.org

March 14, 2016

Centers for Disease Control and Prevention
Division of Select Agents and Toxins
1600 Clifton Road, NE, Mailstop A-46
Atlanta, GA 30329

RE: [Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review of the List of Select Agents and Toxins and Enhanced Biosafety Requirements](#). Docket No. CDC-2015-0006.

Dear Dr. Sosin,

The American Biological Safety Association (ABSA) International welcomes the opportunity to comment on the proposed biennial review of the Select Agent and Toxin List, released on January 19, 2016. ABSA International provides a critical expertise for this topic as many of its members are extensively involved in implementing the Federal Select Agent Program and fulfilling certain roles specified therein.

ABSA International has reviewed the amendments to the Select Agent regulations and provides the following comments for your consideration on the attached Specific Comments Table.

Specific comments for the Biennial Review of the Select Agent and Toxin list and Amendments include requested definitions, clarifications, and further guidance to ensure programs are maintained with integrity. Prevalent concerns and comments are provided regarding proposed changes under the Topics: exclusions and inactivation; security; biocontainment / biosafety; risk assessments; training; and records.

ABSA appreciates the biennial review of the Select Agent program and the proposed modifications that aim to increase the usability of the select agent regulations. The attached comments are respectfully offered for your consideration.

Sincerely,

Melissa Morland, MS, RBP, CBSP
President, American Biological Safety Association

Table: Specific Comments*Table used to make comments specific to document sections and/or paragraphs*

Section Name and/or Section Number	Paragraph/ Figure/Table/Note	Type of comment	Comment (justification for change)	Proposed change
Select Agents and Toxins; Inactivation of a Select Agent	Page 2808, paragraph 3; 42 CFR 73.12	Technical	Include toxins as part of the validation requirements	In addition, a validated sterility testing protocol would have to be conducted in order to ensure that the inactivation method has rendered a select agent nonviable, <u>a toxin non-functional</u> , or regulated nucleic acids non-infectious.
Inactivation of a Select Agent Definitions	Page 2808(C); paragraph 3; 42 CFR 73.12	Technical	Include the word “validated” in the definition of the inactivation method	The definition of inactivation would be established as “a <u>validated</u> method to render a select agent non-viable but retain characteristic of interest for future use, or to render any nucleic acids that can produce infectious forms of any select agent virus non-infectious for future use.”
Inactivation of a Select Agent Definitions	Page 2808(C); paragraph 3; 42 CFR 73.12	Technical	A validated sterility test that is designed and validated in-house appears to be acceptable. Please specify the criteria to be used to show that a test was “validated”.	Define “validated sterility test”
Select Agents and Toxins; Inactivation of a Select Agent	Page 2808(C), paragraph 3; 42 CFR 73.12	Technical	Include a requirement for inactivation process to be repeatable	<u>The process must generate data that demonstrates consistent repeatability.</u>
Inactivation of a Select Agent Definitions	Page 2806(A) 42 CFR 73.12	Technical	Guidance is request for determining an acceptable kill curve and the specifications for acceptable data.	
HHS select agents and toxins; Overlap select agents and toxins	Page 2814, 2815; 42 CFR 73.3, 42 CFR 73.4 (d)(2)(i)(E);	General	Two things are unclear in the proposed change asking for annual reviews of the documents described in this paragraph. First, it is unclear what constitutes a review of these documents; and second, what documentation is required to demonstrate compliance with this review requirement. Please specify the intention, whether it be to require the kill-curve and sterility procedure to be repeated and verified annually, or if this is a review of the data and written procedures, etc.	Add language clarifying the expectations of the “review” and specify the documentation that is required to demonstrate compliance.
Select Agents and Toxins; HHS select agents and toxins	Page 2814 42 CFR 73.3, 42 CFR 73.4 (d)(2)(i)(B);	General	The term “safety margin” used in these paragraphs needs to be defined as it is a subjective term that may vary depending on context. Additionally, the need for a “safety margin” is unclear when there is a requirement to determine a kill curve which identifies the conditions to achieve 100% kill of the select agent or toxin. Use of the “safety margin” term seems unnecessary.	Remove reference to the term “safety margin” in these paragraphs or insert a definition of the term so it is clear what is desired when requiring users to “inactivate by a safety margin”.

Table: Specific Comments*Table used to make comments specific to document sections and/or paragraphs*

Section Name and/or Section Number	Paragraph/ Figure/Table/Note	Type of comment	Comment (justification for change)	Proposed change
Select Agents and Toxins; HHS select agents and toxins	Page 2814 42 CFR 73.3; 42 CFR 73.4; (d)(2)(ii)(D)	Technical	Need to consistently address toxins throughout the document.	”Any viability of a select agent, <u>functionality of a toxin</u> , or infectivity of regulated nucleic acids that can produce infectious forms of any select agent virus that was subjected to a validated inactivation protocol to APHIS or CDC.”
Biosafety	Page 2811; Paragraph 4; 42 CFR 73.12 (a)(1)	General	The additional requirement of written risk assessments for all procedures involving select agent or toxins is excessively burdensome to researchers and the RO/ARO and should be removed. The existing requirements for a biosafety manual and site-specific risk assessment are sufficient in the context of the new requirement to submit the biosafety manual for renewal of registration and when requested by HHS or APHIS. Should the requirements for these written risk assessments remain, guidance is requested for the format of these additional documents.	Remove requirement to have written risk assessments for every procedure involving select agents and toxins.
Training	Page 2812	General	Individuals with direct and routine access to select agents and toxins include a range of personnel including laboratory workers, maintenance staff, RO and AROs, possibly custodial staff, and personnel that access the registered space under full escort. No qualification is described regarding the level of training needed. Personnel at various positions would not be equipped with the technical level that these topics may detail but awareness training, basic knowledge of the facility, emergency response, and security awareness relevant to the trainee’s role and access is recognized.	Request clarification in the regulatory text to assure the acceptability to design training at a level appropriate to the registered person’s role and capability of access to the agent or toxin. Alternatively, a new paragraph or sub-paragraph should be added to this section that acknowledges that the spectrum of training requirements and content should be based on the individual’s role and level of access to agents, rather than requiring the same level of training for all registered persons as well as escorted persons.
Records	Page 2812	General	The requirement to keep laboratory notebooks for inspection purposes is concerning from an intellectual property standpoint. Clarification is requested as to the information needed from the notebooks other than vetting usage if there is an issue with inventory.	Provide language that protects intellectual property interests and specifies information required for more than inventory purposes.